 |
|
|
| |
Longitudinal trajectory of brain volume and cortical thickness in primary infection
|
| |
| |
Just published pdf attached.
CROI 2018 March 4-7 Boston
Download the PDf
Ryan Sanford, Dieter Meyerhoff, Richard W. Price, Beau M. Ances, Serena Spudich, D. Louis Collins
-----------------------------------------------------
LONGITUDINAL COGNITIVE OUTCOMES AFTER TREATMENT IN ACUTE HIV INFECTION (03/16/18)
"Frequency of poor cognitive performance decreased from 26% at baseline, to 10% at 96 week and 6% at 288 weeksafter ART.
Participants included 445 AHI individuals (Fiebig stages I-V) who initiated ART within 30 days after diagnosis and maintained virologic control over the study period. They completed a brief cognitive battery that measured fine motor speed and dexterity, psychomotor speed, and executive functioning at baseline before ART and then at 2 years (n=262) and 6 years (n=47) after ART with sustained viral suppression."
CHANGES IN BRAIN VOLUME AND COGNITION IN MICE EXPOSED IN UTERO TO ABC/ 3TC-ATV/ RTV (03/21/18)
Persistent Detection of HIV RNA+ Cells With ART Started in Fiebig 1 & 2 vs Fiebig 3-5 - (03/07/18)
POORER NEUROCOGNITIVE PERFORMANCE ASSOCIATED WITH CSF HIV DNA DESPITE LONG-TERM ART ACTG HIV Reservoirs Cohort study A5321 (03/09/18) HIV persists in brain of about half despite long-term suppressive ART & is associated with worse cognitive performance.
Asymptomatic Neurocognitive Impairment With HIV Marked by Brain Atrophy - (03/12/18)
Compared with neuropsychologically normal men, those with HIV and asymptomatic neurocognitive impairment (ANI) had frontal white matter atrophy on brain imaging [1]. Longer HIV duration and lower CD4/CD8 ratio predicted brain atrophy. The study involved 85 men with HIV, almost all with a viral load below 50 copies in plasma and cerebrospinal fluid, and 44 demographically similar men without HIV. All underwent anatomical magnetic resonance imaging (MRI), neuropsychological evaluation, and HIV-related lab tests. The researchers used FreeSurfer software to extract grey and white matter regions linked to HIV-related brain injury.
NEUROIMAGING CORRELATES OF FRAILTY, COGNITION, AND HIV (03/09/18) HIV+ frail individuals affected in brain
Amyloid uptake by PET imaging in older HIV+ individuals with cognitive impairment (03/12/18)
BRAIN 18F-FDG PET OF SIV-INFECTED MACAQUES AFTER TREATMENT INTERRUPTION OR INITIATION - (03/09/18)
BRAIN VOLUMES CHANGES AFTER ABC/3TC + EFV OR TDF/FTC + ATV/r AS FIRST LINE ART (03/12/18)
Volumetric MRI studies evaluating the effect of ART initiation over cortical and subcortical grey matter (GM) volume changes are scarce, non-randomized and don't compare the effect of ART regimens with different CNS penetration (CP) and neurotoxicity (NT) profiles.. Randomized, open-label, 24-week pilot clinical trial comparing brain structures (3T-MRI) and neurocognitive changes (NC) in 7 domains after ART initiation with arm1: ABC/3TC+EFV (higher CP and in vitro NT) vs. arm 2: TDF/FTC+ATV/r (lower CP and in vitro NT). Our results suggest that the type of ART selected as initial therapy might have a role preserving the grey matter and the cortical integrity. The regimen with lower CP including drugs with lower in-vitro NT tended to preserve grey matter cortical integrity than the comparator with higher CP and higher in vitro NT. Confirmatory studies are needed.
------------------------------------------------
|
| |
|
|
|
|
|
